Protect against bad breath for 12 hours with new CB12

UK Health Radio previews a unique oral care agent neutralises substances and processes that cause bad breath.............................

 

CB12 is a new, unique, long-lasting mouth rinse proven to prevent and treat bad breath.

Effective for 12 hours, CB12 neutralises substances and processes that cause bad breath.

CB12 combats all three parts of volatile sulphur compounds gases (VSCs) that cause bad breath instead of simply masking it for a short period of time. The unique combination of zinc and chlorhexidine eliminate the “VSCs” from exhaled air and thus also bad breath. CB12 also contains fluoride.

CB12 safe breath oral care agent is available in larger Boots stores and Lloyds Pharmacies nationwide (from November 2012), in both Mint/Menthol and Mild varieties, 250ml, £14.59.

The mouth rinse was developed, evaluated and documented using a gas chromatograph (a specially developed instrument capable of detecting sulphurous gases), of which only a few exist worldwide.

CB12 is easy to use and designed to give the user an exact dose every time. Simply rinse for approximately 30 seconds to 1 minute, gargle and then spit out.

Do not swallow. CB12 is not suitable for those under 12 years or those sensitive to the ingredients.

Dr Thomas Norlin, dentist and a member of the research team that developed CB12 explains, “The discovery and development of the unique active ingredient in CB12 was an incredibly exciting time. CB12’s unique formula, which treats the cause of bad breath, offers welcome relief to halitosis sufferers, ensuring safe breath for 12 hours. We have already seen great successes in other markets. This is a really exciting product for dentists, pharmacists and consumers alike.”

Bad breath is caused by bacteria in the oral cavity, around the teeth and in the gum pockets, as well as in crypts on the back of the tongue. When these bacteria break down food particles, malodorous VSC sulphur gases are formed and these cause bad breath in the exhaled air. Bacteria in the mouth area are naturally occurring and essential for good health.

CB12 neutralises and prevents the origin of these gases. The effect of CB12 is on the gases, not the bacteria, a key differentiator from other products.

 

How I Wore It :: Cotton Candy

I am completely obsessed with my Joe Fresh findings while up in NYC, namely this cotton candy colored pink shirt and perfect shade of blue wide-leg jeans. Throw in the amazingly budget-friendly prices, and I think I have found my new go-to shop for some great closet basics!

The only snag is that they don't currently sell online. Please adjust that part of your business model, stat! I am already having buyer's remorse for not buying MORE than I did. {like this striped turtle neck}

Top it off with some fun gold accessories and we're done! Happy Monday everyone :)

I ride a motorcycle. Do I need insurance?

Motorcyles and mopeds are exempted from Washington mandatory vehicle insurance law, so no, there is no law requiring you to have coverage.

But here's why you may very well want to get it anyway: You are still liable from the state's financial responsibility law. Meaning that if you hit something/someone and it's your fault, it's your responsibility to pay for the damage. And since even a minor scrape or ding to another vehicle can cost hundreds of dollars to fix, state officials believe that many motorcycle owners in Washington voluntarily choose to carry coverage.

Also, if you financed your bike with a loan, your lender will almost certainly require coverage so the lender doesn't lose its money if the bike is wrecked/stolen/vandalized/etc.

The anatomy of a VAP test report

The vertical auto profile (VAP) test is an enhanced lipid profile test. It has been proposed, chiefly by the company Atherotech (), as a more complete test that relies on direct measurement of previously calculated lipid measures. The VAP test is particularly known for providing direct measurements of LDL cholesterol, instead of calculating them through equations ().

At the time of this writing, a typical VAP test report would provide direct measures of the cholesterol content of LDL, Lp(a), IDL, HDL, and VLDL particles. It would also provide additional measures referred to as secondary risk factors, notably particle density patterns and apolipoprotein concentrations. Finally, it would provide a customized risk summary and some basic recommendations for treatment. Below is the top part of a typical VAP test report (from Atherotech), showing measures of the cholesterol content of various particles. LDL cholesterol is combined for four particle subtypes, the small-dense subtypes 4 and 3, and the large-buoyant subtypes 2 and 1. A breakdown by LDL particle subtype is provided later in the VAP report.

In the table above, HDL cholesterol is categorized in two subtypes, the small-dense subtype 2, and the large-buoyant subtype 3. Interestingly, most of the HDL cholesterol in the table is supposedly of the least protective subtype, which seems to be a common finding in the general population. VLDL cholesterol is categorized in a similar way. IDL stands for intermediate-density lipoprotein; this is essentially a VLDL particle that has given off some of its content, particularly its triglyceride (or fat) cargo, but still remains in circulation.

Lp(a) is a special subtype of the LDL particle that is purported to be associated with markedly atherogenic factors. Mainstream medicine generally considers Lp(a) particles themselves to be atherogenic, which is highly debatable. Among other things, cardiovascular disease (CVD) risk and Lp(a) concentration follow a J-curve pattern, and Lp(a)’s range of variation in humans is very large. A blog post by Peter (Hyperlipid) has a figure right at the top that illustrates the former J-curve assertion (). The latter fact, related to range of variation, generally leads to a rather wide normal distribution of Lp(a) concentrations in most populations; meaning that a large number of individuals tend to fall outside Lp(a)’s optimal range and still have a low risk of developing CVD.

Below is the middle part of a typical VAP report, showing secondary risk factors, such as particle density patterns and apolipoprotein concentrations. LDL particle pattern A is considered to be the most protective, supposedly because large-buoyant LDL particles are less likely to penetrate the endothelial gaps, which are about 25 nm in diameter. Apolipoproteins are proteins that bind to fats for their transport in lipoproteins, to be used by various tissues for energy; free fatty acids also need to bind to proteins, notably albumin, to be transported to tissues for use as energy. Redundant particles and processes are everywhere in the human body!

Below is the bottom part of a typical VAP report, providing a risk summary and some basic recommendations. One of the recommendations is “to lower” the LDL target from 130mg/dL to 100mg/dL due to the presence of the checked emerging risk factors on the right, under “Considerations”. What that usually means in practice is a recommendation to take drugs, especially statins, to reduce LDL cholesterol levels. A recent post here and the discussion under it suggest that this would be a highly questionable recommendation in the vast majority of cases ().

What do I think about VAP tests? I think that they are useful in that they provide a lot more information about one’s lipids than standard lipid profiles, and more information is better than less. On the other hand, I think that people should be very careful about what they do with that information. There are even more direct tests that I would recommend before a decision to take drugs is made (, ), if that decision is ever made at all.